Identification

Name
Prazosin
Accession Number
DB00457  (APRD00020)
Type
Small Molecule
Groups
Approved
Description

Prazosin is a selective α-1-adrenergic receptor antagonist used to treat hypertension. It has also been used to decrease urinary obstruction and relieve symptoms associated with symptomatic benign prostatic hyperplasia. α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. Prazosin has also been used in conjunction with cardiac glycosides and diuretics in the management of severe congestive heart failure. It has also been used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma.

Structure
Thumb
Synonyms
  • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
  • 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
  • Prazosina
  • Prazosine
  • Prazosinum
Product Ingredients
IngredientUNIICASInChI Key
Prazosin HydrochlorideX0Z7454B9019237-84-4WFXFYZULCQKPIP-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-prazosin-tab 1mgTablet1 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-prazosin-tab 2mgTablet2 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-prazosin-tab 5mgTablet5 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
MinipressTablet2 mgOralAspri Pharma Canada Inc1983-12-31Not applicableCanada
MinipressCapsule5 mg/1OralPfizer Laboratories Div Pfizer Inc.1994-05-10Not applicableUs
MinipressTablet5 mgOralAspri Pharma Canada Inc1983-12-31Not applicableCanada
MinipressCapsule1 mg/1OralPfizer Laboratories Div Pfizer Inc.1994-05-10Not applicableUs
MinipressTablet1 mgOralAspri Pharma Canada Inc1983-12-31Not applicableCanada
MinipressCapsule2 mg/1OralPfizer Laboratories Div Pfizer Inc.1994-05-10Not applicableUs
Nu-prazo Tab 1mgTablet1 mgOralNu Pharm Inc1992-12-312012-09-04Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-prazo Tab 1mgTablet1 mgOralApotex Corporation1990-12-31Not applicableCanada
Apo-prazo Tab 2mgTablet2 mgOralApotex Corporation1990-12-31Not applicableCanada
Apo-prazo Tab 5mgTablet5 mgOralApotex Corporation1990-12-31Not applicableCanada
Prazosin HydrochlorideCapsule1 mg/1OralTYA Pharmaceuticals2007-02-22Not applicableUs
Prazosin HydrochlorideCapsule1 mg/1OralA S Medication Solutions2007-02-222017-06-20Us
Prazosin HydrochlorideCapsule1 mg/1OralContract Pharmacy Services Pa2017-09-21Not applicableUs
Prazosin HydrochlorideCapsule5 mg/1OralMylan Institutional1998-10-06Not applicableUs
Prazosin HydrochlorideCapsule2 mg/1OralCarilion Materials Management2007-02-22Not applicableUs00093 4068 01 nlmimage10 cc26e637
Prazosin HydrochlorideCapsule1 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1989-02-28Not applicableUs00378 1101 01 nlmimage10 f20e7963
Prazosin HydrochlorideCapsule2 mg/1OralMylan Pharmaceuticals1989-02-28Not applicableUs
International/Other Brands
Hypovase / Minipress Xl (Pfizer) / Pressin / Vasoflex
Categories
UNII
XM03YJ541D
CAS number
19216-56-9
Weight
Average: 383.4011
Monoisotopic: 383.159354185
Chemical Formula
C19H21N5O4
InChI Key
IENZQIKPVFGBNW-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
IUPAC Name
2-[4-(furan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1

Pharmacology

Indication

For treatment of hypertension, symptomatic benign prostatic hyperplasia, and severe congestive heart failure. May also be used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma.

Structured Indications
Pharmacodynamics

Prazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Prazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Prazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Prazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Prazosin results from a decrease in systemic vascular resistance and the parent compound Prazosin is primarily responsible for the antihypertensive activity.

Mechanism of action

Prazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
antagonist
Human
AAlpha-1B adrenergic receptor
antagonist
Human
AAlpha-1D adrenergic receptor
antagonist
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 6
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 7
inhibitor
Human
UAlpha-2A adrenergic receptor
binder
Human
UAlpha-2B adrenergic receptor
binder
Human
Absorption

Well-absorbed from gastrointestinal tract; bioavailability is variable (50 to 85%).

Volume of distribution
Not Available
Protein binding

97%

Metabolism

Primarily hepatic. Several metabolites have been identified in humans and animals (6- O -demethyl, 7- O -demethyl, 2-[1-piperazinyl]-4-amino-6, 7-dimethoxyquinazoline, 2,4-diamino-6,7-dimethoxyquinazoline).

Route of elimination

Animal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by demethylation and conjugation, and excreted mainly via bile and feces. Less extensive human studies suggest similar metabolism and excretion in man.

Half life

2-3 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Prazosin.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Prazosin.Approved
AdrafinilPrazosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Prazosin.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Prazosin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Prazosin.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Prazosin is combined with Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Withdrawn
AmbrisentanPrazosin may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronPrazosin may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostinePrazosin may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Prazosin is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Prazosin.Approved, Investigational
AmitrazPrazosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Prazosin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Prazosin.Approved, Illicit
AmphetamineAmphetamine may increase the hypotensive activities of Prazosin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Prazosin.Approved, Investigational
AmrinonePrazosin may increase the hypotensive activities of Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Prazosin is combined with Amyl Nitrite.Approved
AnisodaminePrazosin may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Prazosin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Apraclonidine.Approved
ArbutaminePrazosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolPrazosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Prazosin.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Prazosin.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Prazosin.Approved
AvanafilAvanafil may increase the hypotensive activities of Prazosin.Approved
AzelnidipinePrazosin may increase the hypotensive activities of Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Prazosin is combined with Azilsartan medoxomil.Approved
AzimilidePrazosin may increase the hypotensive activities of Azimilide.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Prazosin.Experimental
BarbitalBarbital may increase the hypotensive activities of Prazosin.Illicit
BarnidipinePrazosin may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Prazosin.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Benazepril.Approved, Investigational
BencyclanePrazosin may increase the hypotensive activities of Bencyclane.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Prazosin.Approved
BenidipinePrazosin may increase the hypotensive activities of Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypotensive activities of Prazosin.Withdrawn
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Prazosin.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Prazosin.Approved
BethanidineBethanidine may increase the hypotensive activities of Prazosin.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Prazosin.Approved
BietaserpinePrazosin may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostPrazosin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Prazosin.Approved
BitolterolPrazosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Prazosin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Prazosin.Approved, Investigational
BosentanPrazosin may increase the hypotensive activities of Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Prazosin.Approved
BQ-123Prazosin may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Prazosin.Approved
BretyliumThe risk or severity of adverse effects can be increased when Prazosin is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Prazosin.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Prazosin.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prazosin.Approved, Investigational
BucindololBucindolol may increase the orthostatic hypotensive activities of Prazosin.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Prazosin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Prazosin is combined with Bumetanide.Approved
BunazosinPrazosin may increase the antihypertensive activities of Bunazosin.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Prazosin.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Prazosin.Approved
BupropionThe serum concentration of Prazosin can be increased when it is combined with Bupropion.Approved
CadralazinePrazosin may increase the hypotensive activities of Cadralazine.Experimental
CafedrinePrazosin may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.Approved
CandesartanPrazosin may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Prazosin is combined with Candesartan cilexetil.Approved
CandoxatrilPrazosin may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Prazosin.Approved
CarboxyamidotriazolePrazosin may increase the hypotensive activities of Carboxyamidotriazole.Investigational
CaroverinePrazosin may increase the hypotensive activities of Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Prazosin.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Prazosin.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive activities of Prazosin.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Prazosin is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prazosin.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Prazosin.Approved
CicletaninePrazosin may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Cilazapril.Approved
CilnidipinePrazosin may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CinnarizinePrazosin may increase the hypotensive activities of Cinnarizine.Approved, Investigational
CirazolinePrazosin may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolPrazosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Prazosin is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Prazosin.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Prazosin.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Clonidine.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Prazosin.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Prazosin.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Prazosin.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Prazosin.Approved, Investigational
CryptenaminePrazosin may increase the hypotensive activities of Cryptenamine.Approved
CyclopenthiazidePrazosin may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazidePrazosin may increase the hypotensive activities of Cyclothiazide.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Prazosin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Prazosin is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Prazosin.Investigational
DarodipinePrazosin may increase the hypotensive activities of Darodipine.Experimental
DebrisoquinPrazosin may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilPrazosin may increase the hypotensive activities of Delapril.Experimental
DeserpidinePrazosin may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Prazosin.Approved
DetomidinePrazosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Prazosin.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Prazosin is combined with Diclofenamide.Approved
diethylnorsperminePrazosin may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazinePrazosin may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Prazosin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Prazosin is combined with Dinutuximab.Approved
DipivefrinPrazosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Prazosin is combined with Dipyridamole.Approved
DobutaminePrazosin may decrease the vasoconstricting activities of Dobutamine.Approved
DopexaminePrazosin may decrease the vasoconstricting activities of Dopexamine.Investigational
DorzolamidePrazosin may increase the hypotensive activities of Dorzolamide.Approved
DotarizinePrazosin may increase the hypotensive activities of Dotarizine.Investigational
DoxazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Doxazosin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Prazosin.Approved, Investigational
DroxidopaPrazosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetinePrazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Prazosin.Approved
EfonidipinePrazosin may increase the hypotensive activities of Efonidipine.Approved, Investigational
EltrombopagThe serum concentration of Prazosin can be increased when it is combined with Eltrombopag.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Enalapril.Approved, Vet Approved
EnalaprilatPrazosin may increase the hypotensive activities of Enalaprilat.Approved
EndralazinePrazosin may increase the hypotensive activities of Endralazine.Experimental
EpanololEpanolol may increase the orthostatic hypotensive activities of Prazosin.Experimental
EperisonePrazosin may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedrinePrazosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastinePrazosin may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrinePrazosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Prazosin is combined with Eplerenone.Approved
EpoprostenolPrazosin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Prazosin is combined with Eprosartan.Approved
ErgotaminePrazosin may decrease the vasoconstricting activities of Ergotamine.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Prazosin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Prazosin is combined with Etacrynic acid.Approved
EtilefrinePrazosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Prazosin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Prazosin is combined with Felodipine.Approved, Investigational
FendilinePrazosin may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamPrazosin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolPrazosin may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
Ferulic acidPrazosin may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Prazosin.Approved, Investigational
FlunarizinePrazosin may increase the hypotensive activities of Flunarizine.Approved
FormoterolPrazosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Prazosin.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Prazosin is combined with Furosemide.Approved, Vet Approved
GabapentinPrazosin may increase the hypotensive activities of Gabapentin.Approved, Investigational
GallopamilPrazosin may increase the hypotensive activities of Gallopamil.Investigational
GuanabenzPrazosin may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelPrazosin may increase the hypotensive activities of Guanadrel.Approved
GuanazodinePrazosin may increase the hypotensive activities of Guanazodine.Experimental
GuanethidinePrazosin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Prazosin is combined with Guanfacine.Approved, Investigational
GuanoclorPrazosin may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzPrazosin may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanPrazosin may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Prazosin.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Prazosin.Experimental
HexamethoniumPrazosin may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Prazosin.Approved
HexoprenalinePrazosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenaminePrazosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Prazosin.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Prazosin is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Prazosin is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazidePrazosin may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Prazosin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Prazosin.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Prazosin.Approved
IndapamideThe risk or severity of adverse effects can be increased when Prazosin is combined with Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Prazosin.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Prazosin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Prazosin.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Prazosin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Prazosin is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Prazosin.Approved
IsoetarinePrazosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Prazosin.Approved, Vet Approved
IsoprenalinePrazosin may decrease the vasoconstricting activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Prazosin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Prazosin.Approved
KetanserinPrazosin may increase the hypotensive activities of Ketanserin.Investigational
LabetalolLabetalol may increase the orthostatic hypotensive activities of Prazosin.Approved
LacidipinePrazosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotriginePrazosin may increase the hypotensive activities of Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Prazosin.Investigational
LatanoprostPrazosin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Prazosin.Approved
LercanidipinePrazosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Prazosin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Prazosin.Approved, Investigational
LevodopaPrazosin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Prazosin.Approved, Investigational
LidoflazinePrazosin may increase the hypotensive activities of Lidoflazine.Experimental
LinsidominePrazosin may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Lisinopril.Approved, Investigational
LofexidinePrazosin may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Prazosin is combined with Losartan.Approved
LumacaftorThe serum concentration of Prazosin can be decreased when it is combined with Lumacaftor.Approved
MacitentanPrazosin may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfatePrazosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
ManidipinePrazosin may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Prazosin is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Prazosin.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Prazosin is combined with Mecamylamine.Approved
MedetomidinePrazosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MephenterminePrazosin may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Prazosin.Experimental
MetaraminolPrazosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Prazosin is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Prazosin.Approved
MethoserpidinePrazosin may increase the hypotensive activities of Methoserpidine.Experimental
MethoxaminePrazosin may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenaminePrazosin may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Prazosin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Prazosin is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Prazosin.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Prazosin.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Prazosin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Prazosin is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Prazosin is combined with Metolazone.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Investigational
MetyrosinePrazosin may increase the hypotensive activities of Metyrosine.Approved
MibefradilPrazosin may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrinePrazosin may decrease the vasoconstricting activities of Midodrine.Approved
MinaprineMinaprine may increase the hypotensive activities of Prazosin.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Prazosin.Approved
MirabegronPrazosin may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Prazosin.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Prazosin.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Prazosin.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Prazosin.Approved, Investigational
MoxonidinePrazosin may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzoliminePrazosin may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Prazosin.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Prazosin.Approved
NaftopidilPrazosin may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Prazosin.Approved
NaphazolinePrazosin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Prazosin is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Prazosin.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Prazosin is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Prazosin.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Prazosin is combined with Nifedipine.Approved
NiguldipinePrazosin may increase the hypotensive activities of Niguldipine.Experimental
NiludipinePrazosin may increase the hypotensive activities of Niludipine.Experimental
NilvadipinePrazosin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulidePrazosin may increase the hypotensive activities of Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Prazosin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Prazosin.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Prazosin.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Prazosin.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Prazosin is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Prazosin.Approved
NorepinephrinePrazosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrinePrazosin may decrease the vasoconstricting activities of Norfenefrine.Experimental
NylidrinPrazosin may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabPrazosin may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Prazosin.Withdrawn
OctopaminePrazosin may decrease the vasoconstricting activities of Octopamine.Experimental
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Prazosin.Approved, Investigational
OlodaterolPrazosin may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatPrazosin may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalinePrazosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumPrazosin may increase the hypotensive activities of Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Prazosin.Approved
OxyfedrinePrazosin may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolinePrazosin may decrease the vasoconstricting activities of Oxymetazoline.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prazosin.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Prazosin is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Prazosin.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Prazosin.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Prazosin.Approved, Vet Approved
PentoliniumPrazosin may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Prazosin.Approved, Investigational
PerhexilinePrazosin may increase the hypotensive activities of Perhexiline.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Prazosin.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Prazosin.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Prazosin.Approved
PhenoxybenzaminePrazosin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Prazosin.Withdrawn
PhentolaminePrazosin may increase the hypotensive activities of Phentolamine.Approved
PhenylephrinePrazosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolaminePrazosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinacidilPrazosin may increase the hypotensive activities of Pinacidil.Withdrawn
PinaveriumPrazosin may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Prazosin.Approved, Investigational
PirbuterolPrazosin may decrease the vasoconstricting activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Prazosin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Prazosin.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Prazosin.Experimental
PolythiazidePrazosin may increase the hypotensive activities of Polythiazide.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Prazosin.Approved, Investigational
PregabalinPrazosin may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenalterolPrazosin may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylaminePrazosin may increase the hypotensive activities of Prenylamine.Withdrawn
PrimidonePrimidone may increase the hypotensive activities of Prazosin.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Prazosin.Approved
ProcaterolPrazosin may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Prazosin.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Prazosin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Prazosin.Approved
PseudoephedrinePrazosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Prazosin is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Prazosin.Approved
RacepinephrinePrazosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopaminePrazosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Prazosin.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Prazosin.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Prazosin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Prazosin.Approved
RemikirenPrazosin may increase the hypotensive activities of Remikiren.Approved
ReproterolPrazosin may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnaminePrazosin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Prazosin.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Prazosin.Approved, Investigational
RilmenidinePrazosin may increase the hypotensive activities of Rilmenidine.Investigational
RimiterolPrazosin may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatThe risk or severity of adverse effects can be increased when Prazosin is combined with Riociguat.Approved
RisedronatePrazosin may increase the hypotensive activities of Risedronate.Approved, Investigational
RisperidonePrazosin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronPrazosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrinePrazosin may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RituximabPrazosin may increase the hypotensive activities of Rituximab.Approved
RolapitantThe serum concentration of Prazosin can be increased when it is combined with Rolapitant.Approved
RomifidinePrazosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Prazosin.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Prazosin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Prazosin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Prazosin.Approved
SafrazineSafrazine may increase the hypotensive activities of Prazosin.Withdrawn
SalbutamolPrazosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolPrazosin may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanPrazosin may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Prazosin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Prazosin.Approved, Investigational, Vet Approved
SelexipagPrazosin may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Prazosin.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Prazosin.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Prazosin.Approved
SitaxentanPrazosin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Prazosin.Approved
SolabegronPrazosin may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Prazosin.Approved
SpiraprilPrazosin may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Prazosin.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Prazosin.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prazosin.Approved, Investigational
SynephrinePrazosin may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Prazosin.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Prazosin.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Prazosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Prazosin is combined with Telmisartan.Approved, Investigational
TemocaprilPrazosin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Terazosin.Approved
TerbutalinePrazosin may decrease the vasoconstricting activities of Terbutaline.Approved
TeriflunomideThe serum concentration of Prazosin can be increased when it is combined with Teriflunomide.Approved
TerlipressinPrazosin may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilinePrazosin may increase the hypotensive activities of Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Prazosin.Experimental
TetrahydropalmatinePrazosin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Prazosin.Approved, Investigational, Withdrawn
TheodrenalinePrazosin may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Prazosin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Prazosin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Prazosin.Approved, Withdrawn
TibolonePrazosin may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenPrazosin may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Prazosin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Prazosin is combined with Tizanidine.Approved
TolazolinePrazosin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Prazosin.Approved, Withdrawn
Tolfenamic AcidPrazosin may increase the hypotensive activities of Tolfenamic Acid.Approved
TolonidinePrazosin may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Prazosin.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Prazosin.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Prazosin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Prazosin is combined with Trandolapril.Approved
TranilastPrazosin may increase the hypotensive activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Prazosin.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Prazosin.Approved
TravoprostPrazosin may increase the hypotensive activities of Travoprost.Approved
TreprostinilPrazosin may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Prazosin.Approved, Investigational, Nutraceutical
TretoquinolPrazosin may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Prazosin.Approved
TrichlormethiazidePrazosin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinPrazosin may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanPrazosin may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TulobuterolPrazosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Prazosin.Approved, Investigational
UnoprostonePrazosin may increase the hypotensive activities of Unoprostone.Approved
UrapidilPrazosin may increase the hypotensive activities of Urapidil.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Prazosin.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Prazosin.Approved
VerapamilThe risk or severity of adverse effects can be increased when Prazosin is combined with Verapamil.Approved
VincaminePrazosin may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Prazosin.Approved, Investigational
VinpocetinePrazosin may increase the hypotensive activities of Vinpocetine.Investigational
XamoterolPrazosin may decrease the vasoconstricting activities of Xamoterol.Experimental
XipamidePrazosin may increase the hypotensive activities of Xipamide.Experimental
XylazinePrazosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolinePrazosin may increase the hypotensive activities of Xylometazoline.Approved
YM-178Prazosin may decrease the vasoconstricting activities of YM-178.Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Prazosin.Approved, Vet Approved
ZiconotidePrazosin may increase the hypotensive activities of Ziconotide.Approved
ZofenoprilPrazosin may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take without regard to meals.

References

Synthesis Reference

Stig O. E. Lindholm, "A process for the preparation of anhydrous, stable, crystalline delta-form of prazosin hydrochloride." U.S. Patent US4873330, issued 0000.

US4873330
General References
  1. Bawaskar HS, Bawaskar PH: Utility of scorpion antivenin vs prazosin in the management of severe Mesobuthus tamulus (Indian red scorpion) envenoming at rural setting. J Assoc Physicians India. 2007 Jan;55:14-21. [PubMed:17444339]
  2. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301]
  3. Hiraoka Y, Taniguchi T, Tanaka T, Okada K, Kanamaru H, Muramatsu I: Pharmacological characterization of unique prazosin-binding sites in human kidney. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jul;368(1):49-56. Epub 2003 Jun 25. [PubMed:12827214]
  4. Link [Link]
External Links
Human Metabolome Database
HMDB14600
KEGG Compound
C07368
PubChem Compound
4893
PubChem Substance
46508594
ChemSpider
4724
BindingDB
29568
ChEBI
8364
ChEMBL
CHEMBL2
Therapeutic Targets Database
DAP000300
PharmGKB
PA451093
IUPHAR
503
Guide to Pharmacology
GtP Drug Page
HET
XRA
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Prazosin
ATC Codes
C02CA01 — PrazosinC02LE01 — Prazosin and diuretics
AHFS Codes
  • 24:20.00 — Alpha-adrenergic Blocking Agents
PDB Entries
3owx
MSDS
Download (57.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentAlcohol Use Disorders (AUD) / Smoking, Cigarette1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHypertensive1
1Not Yet RecruitingOtherAcute Cardiovascular Disease / Cigarette Smoking Toxicity / Nicotine1
1, 2RecruitingScreeningAlcoholism1
1, 2RecruitingTreatmentAlcohol Dependence1
1, 2RecruitingTreatmentCombat Disorders / Headaches / Mild Traumatic Brain Injury (MTBI) / Post Concussion Syndrome / Posttraumatic Headache / Posttraumatic Migraine1
1, 2Unknown StatusTreatmentNeurogenic Bladder Dysfunction1
2CompletedHealth Services ResearchContinuous Methamphetamine Abuse1
2RecruitingTreatmentAlcohol Use Disorder (AUD) / PTSD1
2RecruitingTreatmentBlood Pressures / Hypertensive / Stress, Psychological1
2TerminatedTreatmentNicotine Dependence1
2Unknown StatusTreatmentAlcohol Abuse / Posttraumatic Stress Disorders1
2Unknown StatusTreatmentAlcoholism1
2Unknown StatusTreatmentFibrosis / Hepatitis C, Chronic1
3CompletedTreatmentAlcohol Dependence / Stress Disorders, Post-Traumatic1
3CompletedTreatmentPTSD / Sleep disorders and disturbances1
3CompletedTreatmentScorpion Envenomation1
3Unknown StatusTreatmentRenal Stones1
4CompletedPreventionHemorrhage, Gastrointestinal / Liver Cirrhosis / Portal Hypertension1
4CompletedTreatmentAlcoholism1
4CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis Medicamentosa / Tachyphylaxis1
4CompletedTreatmentStress Disorders, Post-Traumatic1
4RecruitingOtherDementias1
4RecruitingTreatmentNight-mares, Sleep disturbance / Post Traumatic Stress Disorder (PTSD) / Suicidal Ideation1
4RecruitingTreatmentPost-Traumatic Headaches1
Not AvailableCompletedPreventionAutonomic Dysreflexia1
Not AvailableCompletedTreatmentAlcohol Use Disorder (AUD)1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD)1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD) / Psychomotor Agitation1
Not AvailableCompletedTreatmentAnxiety Disorders / Moods Disorders / Night-mares, Sleep disturbance / Sleeplessness1
Not AvailableCompletedTreatmentCombat Disorders / Sleep disorders and disturbances / Stress Disorders, Post-Traumatic1
Not AvailableCompletedTreatmentSleep disorders and disturbances / Stress Disorders, Post-Traumatic1
Not AvailableRecruitingTreatmentAlcohol Use Disorders (AUD) / Combat Disorders / Stress Disorders, Posttraumatic1
Not AvailableRecruitingTreatmentAlcohol-Related Disorders / Brain Injury / Chronic Diseases / Depression / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries1
Not AvailableRecruitingTreatmentBulimia Nervosa (BN) / Stress Disorders, Post-Traumatic1
Not AvailableRecruitingTreatmentUrinary Retention1
Not AvailableTerminatedTreatmentAlcoholism / Dependence, Cocaine1
Not AvailableTerminatedTreatmentPost-Traumatic Stress Disorder (PTSD) / Sleep Initiation and Maintenance Disorders1
Not AvailableTerminatedTreatmentPosttraumatic Stress Disorder (PTSD)1
Not AvailableTerminatedTreatmentSleep disorders and disturbances / Stress Disorders, Post-Traumatic1
Not AvailableUnknown StatusTreatmentNon PTSD / PTSD1
Not AvailableUnknown StatusTreatmentStress Disorders, Post-Traumatic1
Not AvailableWithdrawnBasic SciencePosttraumatic Stress Disorders1
Not AvailableWithdrawnTreatmentBipolar, Mania / Bipolar, Mixed State1

Pharmacoeconomics

Manufacturers
  • Pfizer laboratories div pfizer inc
  • American therapeutics inc
  • Clonmel healthcare ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Watson laboratories inc
  • Pfizer inc
Packagers
Dosage forms
FormRouteStrength
TabletOral1 mg
TabletOral2 mg
TabletOral5 mg
CapsuleOral1 mg/1
CapsuleOral2 mg/1
CapsuleOral5 mg/1
Prices
Unit descriptionCostUnit
Minipress 5 mg capsule1.97USD capsule
Minipress 2 mg capsule1.14USD capsule
Prazosin HCl 5 mg capsule0.98USD capsule
Prazosin 5 mg capsule0.94USD capsule
Minipress 1 mg capsule0.83USD capsule
Prazosin HCl 2 mg capsule0.57USD capsule
Prazosin 2 mg capsule0.55USD capsule
Prazosin HCl 1 mg capsule0.41USD capsule
Prazosin 1 mg capsule0.4USD capsule
Apo-Prazo 5 mg Tablet0.4USD tablet
Novo-Prazin 5 mg Tablet0.4USD tablet
Nu-Prazo 5 mg Tablet0.4USD tablet
Vasoflex hd caplet0.38USD caplet
Vasoflex forte capsule0.29USD capsule
Apo-Prazo 2 mg Tablet0.29USD tablet
Novo-Prazin 2 mg Tablet0.29USD tablet
Nu-Prazo 2 mg Tablet0.29USD tablet
Apo-Prazo 1 mg Tablet0.22USD tablet
Novo-Prazin 1 mg Tablet0.22USD tablet
Nu-Prazo 1 mg Tablet0.22USD tablet
Vasoflex tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)279 °CPhysProp
water solubility0.5 mg/mL (HCl salt)Sigma Aldrich
logP1.3Not Available
Caco2 permeability-4.36ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.693 mg/mLALOGPS
logP1.93ALOGPS
logP1.65ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area106.95 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity104.5 m3·mol-1ChemAxon
Polarizability40.49 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9479
Caco-2 permeable+0.8298
P-glycoprotein substrateSubstrate0.7193
P-glycoprotein inhibitor INon-inhibitor0.5747
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.6405
CYP450 2C9 substrateNon-substrate0.8773
CYP450 2D6 substrateNon-substrate0.7641
CYP450 3A4 substrateSubstrate0.7577
CYP450 1A2 substrateNon-inhibitor0.8434
CYP450 2C9 inhibitorNon-inhibitor0.9278
CYP450 2D6 inhibitorNon-inhibitor0.9685
CYP450 2C19 inhibitorNon-inhibitor0.9169
CYP450 3A4 inhibitorNon-inhibitor0.7608
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8049
Ames testNon AMES toxic0.5581
CarcinogenicityNon-carcinogens0.9199
BiodegradationNot ready biodegradable0.9818
Rat acute toxicity2.3304 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8352
hERG inhibition (predictor II)Inhibitor0.8489
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-001i-0019000000-9cca43997ddcbdd78e84
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0009000000-9da934e12af818eb0a08
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0009000000-85316e57dd3fefac386d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0019000000-09972bca73a43a1b73ab
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0002-1597000000-48d7b8ba991427bab5c2
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0002-7491000000-4258e4db8045e56fe90f
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0002-0093000000-bffbfeafa12bdaf90f1d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0009000000-d13122c92100f1c0a02e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0009000000-b0b57af432244c705c26
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000t-1289000000-c6fe1f53648d640102aa
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000t-3292000000-6907f1985350ad49c47b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000t-8490000000-f9e0f1ad0c30225b7de2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0009000000-77125e491b72f0b0adae
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0029000000-4492a1b0f9df7854cc06
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0f8j-0392000000-b5c53dfdec441c727d1f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001r-0149000000-db377c2ba80a2269be91

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Quinazolinamines / 2-heteroaryl carboxamides / Anisoles / Dialkylarylamines / Furoic acid and derivatives / Alkyl aryl ethers / Aminopyrimidines and derivatives / Imidolactams / Tertiary carboxylic acid amides / Heteroaromatic compounds
show 7 more
Substituents
N-arylpiperazine / Quinazolinamine / Diazanaphthalene / Quinazoline / 2-heteroaryl carboxamide / Furoic acid or derivatives / Anisole / Dialkylarylamine / Alkyl aryl ether / Aminopyrimidine
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aromatic ether, monocarboxylic acid amide, furans, quinazolines, piperazines (CHEBI:8364)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Chang HK, Hsu FL, Liu IM, Cheng JT: Stimulatory effect of cinnamic acid analogues on alpha1A-adrenoceptors in-vitro. J Pharm Pharmacol. 2003 Jun;55(6):833-7. [PubMed:12841945]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876]
  3. Morris DP, Price RR, Smith MP, Lei B, Schwinn DA: Cellular trafficking of human alpha1a-adrenergic receptors is continuous and primarily agonist-independent. Mol Pharmacol. 2004 Oct;66(4):843-54. Epub 2004 Jul 16. [PubMed:15258254]
  4. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623]
  5. Suzuki Y, Kanada A, Okaya Y, Aisaka K: Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs. Eur J Pharmacol. 2000 Apr 7;394(1):123-30. [PubMed:10771044]
  6. Tomiyama Y, Kobayashi K, Tadachi M, Kobayashi S, Inada Y, Kobayashi M, Yamazaki Y: Expressions and mechanical functions of alpha1-adrenoceptor subtypes in hamster ureter. Eur J Pharmacol. 2007 Nov 14;573(1-3):201-5. Epub 2007 Jul 6. [PubMed:17658513]
  7. Zacharia J, Hillier C, MacDonald A: Alpha1-adrenoceptor subtypes involved in vasoconstrictor responses to exogenous and neurally released noradrenaline in rat femoral resistance arteries. Br J Pharmacol. 2004 Mar;141(6):915-24. Epub 2004 Feb 23. [PubMed:14980979]
  8. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Al-Damluji S, Shen WB, White S, Barnard EA: alpha(1B) adrenergic receptors in gonadotrophin-releasing hormone neurones: relation to Transport-P. Br J Pharmacol. 2001 Jan;132(1):336-44. [PubMed:11156594]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876]
  4. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41. [PubMed:12270758]
  5. Sharpe IA, Thomas L, Loughnan M, Motin L, Palant E, Croker DE, Alewood D, Chen S, Graham RM, Alewood PF, Adams DJ, Lewis RJ: Allosteric alpha 1-adrenoreceptor antagonism by the conopeptide rho-TIA. J Biol Chem. 2003 Sep 5;278(36):34451-7. Epub 2003 Jun 24. [PubMed:12824165]
  6. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623]
  7. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Nagaoka Y, Ahmed M, Hossain M, Bhuiyan MA, Ishiguro M, Nakamura T, Watanabe M, Nagatomo T: Amino acids of the human alpha1d-adrenergic receptor involved in antagonist binding. J Pharmacol Sci. 2008 Jan;106(1):114-20. Epub 2008 Jan 11. [PubMed:18187928]
  2. Yamamoto Y, Koike K: alpha(1)-Adrenoceptor subtypes in the mouse mesenteric artery and abdominal aorta. Br J Pharmacol. 2001 Nov;134(5):1045-54. [PubMed:11682453]
  3. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name
KCNH6
Uniprot ID
Q9H252
Uniprot Name
Potassium voltage-gated channel subfamily H member 6
Molecular Weight
109923.705 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name
KCNH7
Uniprot ID
Q9NS40
Uniprot Name
Potassium voltage-gated channel subfamily H member 7
Molecular Weight
134998.525 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]
  2. Pan G, Winter TN, Roberts JC, Fairbanks CA, Elmquist WF: Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells. Mol Pharm. 2010 Feb 1;7(1):138-45. doi: 10.1021/mp900177r. [PubMed:19886673]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  3. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783]
  4. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956]
  5. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV: Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9. [PubMed:9380680]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956]
  2. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. [PubMed:11437380]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34